Prevas has signed an agreement for the acquisition of the company MEDQURE. The company provides regulatory services and consultation to companies worldwide with medical devices. The acquisition further strengthens Prevas' position in life science.
MEDQURE is a Stockholm-based, cutting-edge company in medical technology regulations and quality assurance. The company has extensive experience of helping customers with regulatory strategies, setting up new or improving quality assurance systems, CE marking and extensive experience of working with notified bodies, FDA applications, GAP analyses, compliance with directives/regulations such as MDD/MDR, IVD/IVDR, EMC, ROHS, REACH, RED, etc. as well as assuring the quality of development activities. MEDQURE also holds several courses in life science, for example in CE marking medical technology, usability, medical device software, the EN 60601/EN 61010 standards and IVDR. These courses are conducted online/on site and tailored to customer needs.
MEDQURE's customers range from international companies to small and medium-sized companies and start-ups. Besides Swedish companies, there are also Norwegian, Danish and American companies, for example.
"We know each other well from before, and I'm looking forward to joining in the further development of our strong range of services in life science," says Robert Tönhardt, head of life science operations at Prevas. "Here we help companies to comply with rules and regulatory requirements, quickly getting their products on the market and developing innovative solutions," says Robert Tönhardt.
Rapid development in medical technology and the pharmaceutical industry, the increased digitalization of healthcare and preventive care in combination with regulatory changes in medical technology entail an increasing need for cutting-edge expertise in quality assurance.
"Prevas' strong expertise in life science suits us quite well and I, together with my three specialists, see that we will complement each other in a very good way based on a broadened range of services and wider network," says Micael Johansson, CEO at MEDQURE. "It gives us new opportunities to expand our business and to reach out and provide greater added value to more customers."
Global demand for new drugs and medical technology continues to grow. More and more people are feeling better, we have an older and healthier population at the same time as we are seeing more ill-health due to diseases of affluence. There is a major need for investments in innovation and digitalization in healthcare. Add to that, changes in regulatory requirements for medical devices and the need for consultation services, and we have an area with very strong demand.
MEDQUIRE will become a part of Prevas in July, and the acquisitions of NIMIO AB (company name) and MEDQURE (brand/trademark) are expected to have a marginally positive impact on Prevas earnings per share during the current financial year.
More about Prevas services in life science.
For more information, please contact:
Robert Tönhardt, Director Life Science, Prevas AB
Mobile: +46 703 79 07 03, email: email@example.com
Micael Johansson, Senior Quality & Regulatory Consultant and CEO, Medqure
Mobile: +46 730 70 10 44, email: firstname.lastname@example.org